Celldex Therapeutics Inc (CLDX)

May 23, 2025

Celldex Therapeutics’ SWOT analysis: barzolvolimab stock poised for growth By Investing.com - Investing.com South Africa

May 23, 2025

May 23, 2025

Global Cholera Vaccines Market in 2025-2032 Detailed Study - openPR.com

May 23, 2025

May 22, 2025

Celldex Therapeutics’ SWOT analysis: barzolvolimab stock poised for growth - Investing.com

May 22, 2025

May 19, 2025

BNP Paribas Financial Markets Raises Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - Defense World

May 19, 2025

May 13, 2025

Celldex Therapeutics Reports Increased Losses Amid R&D Expansion - TipRanks

May 13, 2025

May 12, 2025

Morgan Stanley Cuts Celldex Therapeutics (NASDAQ:CLDX) Price Target to $43.00 - Defense World

May 12, 2025

May 12, 2025

UBS Group Cuts Celldex Therapeutics (NASDAQ:CLDX) Price Target to $38.00 - Defense World

May 12, 2025

May 12, 2025

The Goldman Sachs Group Cuts Celldex Therapeutics (NASDAQ:CLDX) Price Target to $31.00 - Defense World

May 12, 2025

May 11, 2025

Hsbc Holdings PLC Takes $233,000 Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - Defense World

May 11, 2025

May 11, 2025

Celldex Therapeutics Q1 2025 Earnings: EPS of ($0.81) Misses Est - GuruFocus

May 11, 2025

May 10, 2025

UBS Lowers Price Target for Celldex Therapeutics (CLDX) to $38 | - GuruFocus

May 10, 2025

May 10, 2025

First Trust Advisors LP Trims Holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - Defense World

May 10, 2025

May 09, 2025

Celldex Therapeutics (CLDX): Analyst Lowers Price Target But Mai - GuruFocus

May 09, 2025

May 09, 2025

Morgan Stanley Updates Price Target for Celldex Therapeutics (CL - GuruFocus

May 09, 2025

May 09, 2025

Goldman Sachs Lowers Price Target for Celldex Therapeutics (CLDX) | CLDX Stock News - GuruFocus

May 09, 2025

May 09, 2025

Celldex (CLDX) Target Price Reduced by Analyst Following Q1 Repo - GuruFocus

May 09, 2025

May 09, 2025

H.C. Wainwright cuts Celldex stock price target to $50 from $80 - Investing.com Canada

May 09, 2025

May 09, 2025

UBS Adjusts Price Target on Celldex Therapeutics to $38 From $44, Maintains Buy Rating - marketscreener.com

May 09, 2025

May 09, 2025

Celldex Therapeutics, Inc. (CLDX): Among the Best Cancer Stocks to Invest in for Long-Term Gain - Insider Monkey

May 09, 2025

May 09, 2025

Celldex (CLDX) Target Price Reduced by Analyst Following Q1 Report | CLDX Stock News - GuruFocus

May 09, 2025

May 09, 2025

Celldex: Q1 Earnings Snapshot - New Haven Register

May 09, 2025

May 08, 2025

10 Best Cancer Stocks to Invest in for Long-Term Gains - Insider Monkey

May 08, 2025

May 08, 2025

Celldex Therapeutics (CLDX) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance

May 08, 2025

May 08, 2025

Celldex Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 08, 2025

May 08, 2025

Earnings Flash (CLDX) Celldex Therapeutics Reports Q1 Revenue $695K - marketscreener.com

May 08, 2025

May 08, 2025

Earnings Flash (CLDX) Celldex Therapeutics Reports Q1 Loss $0.81 Per Share, vs. FactSet Est of $-0.75 - marketscreener.com

May 08, 2025

May 08, 2025

Celldex Reports First Quarter 2025 Financial Results and Provides Corporate Update - Bluefield Daily Telegraph

May 08, 2025

May 07, 2025

Stock Market Recap: Celldex Therapeutics Inc (CLDX) Concludes at 18.40, a -9.31 Surge/Decline - DWinneX

May 07, 2025

May 07, 2025

Cantor Fitzgerald maintains Celldex stock Overweight with $67 target By Investing.com - Investing.com Canada

May 07, 2025

May 06, 2025

Celldex Therapeutics (CLDX) Receives Reiterated 'Buy' Rating fro - GuruFocus

May 06, 2025

May 06, 2025

Interesting CLDX Put And Call Options For June 20th - Nasdaq

May 06, 2025

May 06, 2025

Celldex Therapeutics (CLDX) Receives Reiterated 'Buy' Rating from HC Wainwright | CLDX Stock News - GuruFocus

May 06, 2025

May 05, 2025

Celldex Presents Histology Data from Phase 2 Study of Barzolvolimab in EoE Supporting Potential of Mast Depleting Agent in this Difficult to Treat Disease - The Manila Times

May 05, 2025

May 05, 2025

New Clinical Data Reveals Breakthrough Potential for Celldex's EoE Treatment at Major Medical Conference - Stock Titan

May 05, 2025

May 03, 2025

Celldex Therapeutics (CLDX) Projected to Post Quarterly Earnings on Monday - Defense World

May 03, 2025

May 02, 2025

Celldex: Q4 Earnings Snapshot - Barchart.com

May 02, 2025

May 02, 2025

Market Insights: Celldex Therapeutics Inc (CLDX)’s Notable Drop of -0.58, Closing at 20.71 - DWinneX

May 02, 2025

May 02, 2025

A look into Celldex Therapeutics Inc (CLDX)’s deeper side - Sete News

May 02, 2025

May 02, 2025

Invesco Ltd. Has $1.06 Million Stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - Defense World

May 02, 2025

May 02, 2025

Celldex Therapeutics, Inc. (NASDAQ:CLDX) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World

May 02, 2025

May 01, 2025

Celldex Therapeutics Inc’s results are impressive - uspostnews.com

May 01, 2025

Apr 30, 2025

The Attractiveness of Investing In Celldex Therapeutics Inc (CLDX) is Growing - knoxdaily.com

Apr 30, 2025

Apr 29, 2025

Celldex Therapeutics (NASDAQ:CLDX) Coverage Initiated by Analysts at Canaccord Genuity Group - Defense World

Apr 29, 2025

Apr 28, 2025

Analyst Expectations For Celldex Therapeutics's Future - Benzinga

Apr 28, 2025

Apr 28, 2025

This Kohl's Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday - Benzinga

Apr 28, 2025

Apr 28, 2025

Canaccord Genuity Initiates Coverage of Celldex Therapeutics (CLDX) with Buy Recommendation - Nasdaq

Apr 28, 2025

Apr 28, 2025

Canaccord Genuity Initiates Coverage on Celldex Therapeutics With Buy Rating, $64 Price Target - marketscreener.com

Apr 28, 2025